29 July 2021

Pro-Con debate session 1

Watch the replay

Agenda

  • Peter Dorfmüller // A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH
  • Duncan Stewart  // Remnants of lost pulmonary vasculature may be re-engaged in PAH
  • David Systrom // Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs
  • Roham Zamanian // Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs

Poll results

Topic A

Which statement do you agree with?

PRO: A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH - 12.82%

CON: Remnants of lost pulmonary vasculature may be re-engaged in PAH - 87.18%

 

2. Now you have heard the debate, which statement do you agree with?

PRO: A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH - 5%

CON: Remnants of lost pulmonary vasculature may be re-engaged in PAH - 95%

 

Topic B

3. Which statement do you agree with?

PRO: Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs - 69%

CON: Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs - 31%

 

4. Now you have heard the debate, which statement do you agree with?

PRO: Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs - 45.16%

CON: Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs - 54.84%

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg